Emergent Bilateral Face-lift Hematoma: A Case Report.

The face-lift, or rhytidectomy, is a common surgical procedure in the United States. Facial hematoma is the most frequent complication after face-lift. Sometimes an emergent expanding hematoma may require general anesthesia and can present difficulty in securing the airway. This article reviews the frequency and causes of an expanding hematoma and how it affects anesthesia care. The case summary describes an emergent bilateral hematoma after a face-lift in a 50-year-old woman, the emergency treatment, and her subsequent recovery. Details of the procedure are provided. The purpose of examining this case is to inform and educate anesthesia providers about the possibility of a common face-lift complication and how to prepare for securing the difficult airway in this situation.

Postmenopausal females and the link between oral bisphosphonates and osteonecrosis of the jaw: a clinical review.

PURPOSE: To increase awareness for nurse practitioners (NPs) of new information concerning the plausible link between the oral bisphosphonate drug classification and necrosis in the jaw. DATA SOURCES: Selected research and clinical articles. In addition, several peer-reviewed, refereed medical and dental journals were consulted. CONCLUSIONS: Oral bisphosphonates are commonly prescribed by NPs for postmenopausal females with the diagnosis of osteoporosis to arrest bone loss and preserve bone density. Recent reports have shown a link between these medications and osteonecrosis of the jaw, which is a complication resulting in necrotic bone inside the mouth. IMPLICATIONS FOR PRACTICE: NPs must be able to determine early warning signs of osteonecrosis to ensure prompt referral to a dental specialist in order to prevent irreversible sequelae. Because of the aging population, osteoporosis is predicted to increase; therefore, treatment with these drugs and the side effects that go along with them will most likely also increase.

Bisphosphonate-associated osteonecrosis of the jaw: patient care considerations: overview for the orthopaedic nursing healthcare professional.

An emerging problem for patients taking bisphosphonate (BSP) medications for osteoporosis or cancer therapies has been the occurrence of osteonecrosis of the jaws (ONJ), most often after dental surgical procedures. ONJ can be a persistent and discomforting condition that can also be refractory to various therapies. This article will overview the pathophysiology of ONJ, the proposed causal relationship between BSP use and ONJ, and the current guidelines for dental care of a patient who will be, or is taking, this class of medications. Included are suggested guidelines for the orthopaedic nurse who may interact with these patients. Alternate names for this malady are as follows:

Complication related to bisphosphonate therapy: osteonecrosis of the jaw.

Bisphosphonates are synthetic analogs of naturally occurring pyrophosphates, and they inhibit osteoclast-mediated bone resorption. They are widely used for the prevention and treatment of osteoporosis, treatment of Paget's disease of bone, management of metastatic cancer in bone, and short-term management of acute hypercalcemia. Osteonecrosis of the jaw is an adverse drug effect of bisphosphonates, and it typically presents as infection and necrotic bone in the mandible or maxilla. This article discusses pharmacology of bisphosphonates and osteonecrosis of the jaw, including its contributing factors, pathophysiology, prevention, and management, as well as appropriate nursing interventions.